O	0	10	Increasing
O	11	20	Adherence
O	21	23	to
O	24	32	Adjuvant
O	33	40	Hormone
O	41	48	Therapy
O	49	54	Among
O	55	63	Patients
O	64	68	With
O	69	75	Breast
O	76	82	Cancer
O	82	83	:
O	84	85	A
O	86	91	Smart
O	92	97	Phone
O	98	101	App
O	101	102	-
O	102	107	Based
O	108	113	Pilot
O	114	119	Study
O	119	120	.

O	121	125	This
O	126	131	study
O	132	138	tested
O	139	142	the
O	143	154	feasibility
O	155	158	and
O	159	167	efficacy
O	168	170	of
O	171	176	using
O	177	178	a
B-intervention	179	183	text
I-intervention	183	184	-
I-intervention	184	189	based
O	190	202	intervention
O	203	205	to
O	206	214	increase
O	215	225	initiation
O	225	226	,
O	227	235	decrease
O	236	251	discontinuation
O	251	252	,
O	253	256	and
O	257	264	improve
O	265	274	adherence
O	275	277	as
O	278	288	prescribed
O	289	291	to
O	292	300	adjuvant
O	301	308	hormone
O	309	316	therapy
O	317	318	(
O	318	321	AHT
O	321	322	)
O	323	328	among
O	329	338	hyphenate
O	339	343	post
O	343	344	-
O	344	354	menopausal
O	355	361	breast
O	362	368	cancer
O	369	378	survivors
O	378	379	.

O	380	383	The
O	384	385	3
O	385	386	-
O	386	391	month
O	392	404	intervention
O	405	414	consisted
O	415	417	of
O	418	423	daily
O	424	428	text
O	429	436	message
O	437	446	reminders
O	447	449	to
O	450	454	take
O	455	465	medication
O	465	466	,
O	467	474	coupled
O	475	479	with
O	480	481	a
O	482	489	dynamic
O	490	491	(
O	491	493	eg
O	493	494	,
O	495	503	feedback
O	504	506	on
O	507	515	progress
O	515	516	)
O	517	525	tailored
O	526	538	intervention
O	539	544	using
O	545	551	weekly
O	552	563	interactive
O	564	571	surveys
O	572	581	delivered
O	582	584	by
O	585	586	a
O	587	597	smartphone
O	598	601	app
O	601	602	.

O	603	607	Five
O	608	614	clinic
O	615	620	sites
O	621	627	within
O	628	631	the
O	632	640	Alliance
O	641	644	for
O	645	653	Clinical
O	654	660	Trials
O	661	663	in
O	664	672	Oncology
O	673	685	participated
O	685	686	.

O	687	694	Hormone
O	695	701	levels
O	702	706	were
O	707	715	measured
O	716	721	prior
O	722	724	to
O	725	728	AHT
O	729	739	initiation
O	740	743	and
O	744	746	at
O	747	752	study
O	753	757	exit
O	757	758	.

O	759	761	Of
O	762	765	the
B-total-participants	766	768	39
O	769	777	patients
O	778	787	recruited
O	788	790	to
O	791	794	the
O	795	800	pilot
O	801	806	study
O	806	807	,
B-total-participants	808	810	27
O	811	812	(
O	812	814	69
O	814	815	.
O	815	816	2
O	816	817	%
O	817	818	)
O	819	828	completed
O	829	832	all
O	833	838	study
O	839	851	requirements
O	852	853	(
O	853	862	completed
O	863	867	both
O	868	871	the
O	872	880	baseline
O	881	884	and
O	885	888	the
O	889	893	exit
O	894	901	surveys
O	901	902	,
O	903	907	both
O	908	913	blood
O	914	919	draws
O	919	920	,
O	921	924	and
O	925	928	did
O	929	932	not
O	933	937	miss
O	938	942	more
O	943	947	than
O	948	949	2
O	950	956	weekly
O	957	964	surveys
O	964	965	)
O	965	966	.

O	967	978	Significant
O	979	991	improvements
O	992	996	were
O	997	1005	observed
O	1006	1009	pre
O	1009	1010	-
O	1011	1013	to
O	1014	1030	postintervention
O	1031	1034	for
O	1035	1039	self
O	1039	1040	-
O	1040	1048	reported
B-outcome	1049	1059	medication
I-outcome	1060	1069	adherence
O	1070	1071	(
O	1071	1072	P
O	1073	1074	=
O	1075	1076	.
O	1076	1079	015
O	1079	1080	)
O	1080	1081	,
B-outcome	1082	1088	mental
I-outcome	1089	1095	health
I-outcome	1096	1107	functioning
O	1108	1109	(
O	1109	1110	P
O	1111	1112	=
O	1113	1114	.
O	1114	1117	007
O	1117	1118	)
O	1118	1119	,
O	1120	1123	and
B-outcome	1124	1133	perceived
I-outcome	1134	1140	stress
O	1141	1142	(
O	1142	1143	P
O	1144	1145	=
O	1146	1147	.
O	1147	1149	04
O	1149	1150	)
O	1150	1151	.

O	1152	1163	Significant
O	1164	1173	decreases
O	1174	1176	in
B-outcome	1177	1186	estradiol
I-outcome	1186	1187	,
I-outcome	1188	1196	estrogen
I-outcome	1196	1197	,
I-outcome	1198	1201	and
I-outcome	1202	1209	estrone
I-outcome	1210	1217	hormone
I-outcome	1218	1224	levels
O	1225	1229	were
O	1230	1238	observed
O	1239	1243	from
O	1244	1252	baseline
O	1253	1255	to
O	1256	1261	study
O	1262	1266	exit
O	1267	1268	(
O	1268	1269	P
O	1270	1271	<
O	1272	1273	.
O	1273	1276	001
O	1276	1277	)
O	1277	1278	,
O	1279	1289	indicating
O	1290	1293	the
O	1294	1302	accuracy
O	1303	1305	of
O	1306	1310	self
O	1310	1311	-
O	1311	1319	reported
O	1320	1323	AHT
O	1324	1333	adherence
O	1333	1334	.

O	1335	1347	Participants
O	1348	1349	(
O	1349	1351	91
O	1351	1352	.
O	1352	1353	9
O	1353	1354	%
O	1354	1355	)
O	1356	1359	and
O	1360	1370	physicians
O	1371	1372	(
O	1372	1375	100
O	1375	1376	%
O	1376	1377	)
O	1378	1384	agreed
O	1385	1389	that
O	1390	1401	participant
O	1402	1415	participation
O	1416	1418	in
O	1419	1422	the
O	1423	1435	intervention
O	1436	1439	was
O	1440	1450	beneficial
O	1450	1451	.

O	1452	1455	The
O	1456	1463	results
O	1464	1466	of
O	1467	1471	this
O	1472	1477	pilot
O	1478	1483	study
O	1484	1495	established
O	1496	1499	the
O	1500	1507	general
O	1508	1519	feasibility
O	1520	1523	and
O	1524	1532	efficacy
O	1533	1535	of
O	1536	1538	an
O	1539	1542	app
O	1542	1543	-
O	1543	1548	based
O	1549	1561	intervention
O	1562	1564	to
O	1565	1572	support
O	1573	1580	patient
O	1581	1584	AHT
O	1585	1594	adherence
O	1594	1595	.

O	1596	1602	Larger
O	1603	1613	controlled
O	1613	1614	,
O	1615	1625	randomized
O	1626	1632	trials
O	1633	1636	are
O	1637	1643	needed
O	1644	1646	to
O	1647	1654	examine
O	1655	1658	the
O	1659	1672	effectiveness
O	1673	1675	of
O	1676	1679	the
O	1680	1683	app
O	1683	1684	-
O	1684	1689	based
O	1690	1702	intervention
O	1703	1705	in
O	1706	1715	improving
O	1716	1719	AHT
O	1720	1723	and
O	1724	1731	quality
O	1732	1734	of
O	1735	1739	life
O	1740	1745	among
O	1746	1752	breast
O	1753	1759	cancer
O	1760	1769	survivors
O	1769	1770	.
